Találati lista | Tudóstér

001-es BibID:	BIBFORM072318
Első szerző:	Kocsis Judit (onkológus)
Cím:	First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer : efficacy and Safety Analysis / Judit Kocsis, Éva Szekanecz, Ali Bassam, Andrea Uhlyarik, Zsuzsanna Pápai, Gábor Rubovszky, Emese Mezősi, Károly Rucz, Ildikó Garai, Endre Nagy, Iván Uray, Zsolt Horváth
Dátum:	2019
Megjegyzések:	Background Medullary thyroid cancer (MTC) is a rare disease,the prognosis of advanced and metastatic disease is poor andfew therapeutic options are available in this setting. Based onthe results of phase II and III studies with sorafenib in differentiatedthyroid cancer and the lack of availability of registeredtyrosine kinase inhibitors, vandetabin and cabozantinib in Hungary,we designed a uncontrolled, prospective efficacy andsafety study of patients with metastatic MTC treated with firstlinesorafenib in five Hungarian oncology centers.Methods Ten consecutive patients with progressive or symptomaticmetastatic MTC were included and started sorafenib400 mg twice a day between June 2012 and March 2016. Theprimary end point was median progression-free survival(mPFS). Secondary endpoints included disease control rate,biochemical response, symptomatic response and toxicity.Results Four patients achieved partial remission (40 %) accordingto RECIST 1.1 evaluation. Five patients had stable diseasebeyond 12 months (50 %) and one patient had progressivedisease (10 %). Median PFS was 19.1 months. The disease controlrate was 90 %. Association between radiologic responseand biochemical or symptomatic response was inconsistent.Most common side effects were Grade 1-2 fatigue (60 %),palmar-plantar erythrodysesthesia, rash/dermatitis 50-50 %,alopecia 40 %.Conclusions In our prospective case series in patients withMTC first-line sorafenib showed at least similar efficacy as inother small phase II trials and case reports. Based on comparableefficacy with registered tyrosine kinase inhibitors and it'smanageable toxicity profile, we believe that sorafenib has rolein the sequential treatment of MTC.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Experimental and clinical endocrinology & diabetes. - 127 : 4 (2019), p. 240-246. -
További szerzők:	Szekanecz Éva (1968-) (onkológus szakorvos) Bassam, Ali Uhlyarik Andrea Pápai Zsuzsanna Rubovszky Gábor Mezősi Emese Rucz Károly Garai Ildikó (1966-) (radiológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Uray Iván Péter (1970-) (kutatóorvos) Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus)
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM116667
035-os BibID:	(Scopus)85170843236 (WOS)001015187100005 (cikkazonosító)e220134
Első szerző:	Solymosi Tamás
Cím:	Considerable interobserver variation calls for unambiguous definitions of thyroid nodule ultrasound characteristics / Solymosi Tamas, Hegedűs Laszlo, Bonnema Steen J., Frasoldati Andrea, Jambor Laszlo, Karanyi Zsolt, Kovacs Gabor L., Papini Enrico, Rucz Karoly, Russ Gilles, Nagy Endre V.
Dátum:	2023
ISSN:	2235-0640 2235-0802
Megjegyzések:	Thyroid nodule ultrasound characteristics are used as an indication for fine-needle aspiration cytology, usually as the basis for Thyroid Imaging Reporting and Data System (TIRADS) score calculation. Few studies on interobserver variation are available, all of which are based on analysis of preselected still ultrasound images and often lack surgical confirmation.Methods: After the blinded online evaluation of video recordings of the ultrasound examinations of 47 consecutive malignant and 76 consecutive benign thyroid lesions, 7 experts from 7 thyroid centers answered 17 TIRADS-related questions. Surgical histology was the reference standard. Interobserver variations of each ultrasound characteristic were compared using Gwet's AC1 inter-rater coefficients; higher values mean better concordance, the maximum being 1.0.Results: On a scale from 0.0 to 1.0, the Gwet's AC1 values were 0.34, 0.53, 0.72, and 0.79 for the four most important features in decision-making, i.e. irregular margins, microcalcifications, echogenicity, and extrathyroidal extension, respectively. The concordance in the discrimination between mildly/moderately and very hypoechogenic nodules was 0.17. The smaller the nodule size the better the agreement in echogenicity, and the larger the nodule size the better the agreement on the presence of microcalcifications. Extrathyroidal extension was correctly identified in just 45.8% of the cases.Conclusions: Examination of video recordings, closely simulating the real-world situation, revealed substantial interobserver variation in the interpretation of each of the four most important ultrasound characteristics. In view of the importance for the management of thyroid nodules, unambiguous and widely accepted definitions of each nodule characteristic are warranted, although it remains to be investigated whether this diminishes observer variation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk cytology thyroid cancer thyroid nodule TIRADS ultrasound
Megjelenés:	European Thyroid Journal. - 12 : 2 (2023), p. 1-11. -
További szerzők:	Hegedűs László Dávid (1992-) (PhD hallgató) Bonnema, Steen Joop Frasoldati, Andrea Jámbor László (1960-) (radiológus) Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Kovács Gábor L. (Szeged) Papini, Enrico Rucz Károly Russ, Gilles Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM092856
Első szerző:	Solymosi Tamás
Cím:	Ultrasound-Based Indications for Thyroid Fine-Needle Aspiration: Outcome of a TIRADS-Based Approach versus Operators' Expertise / Tamas Solymosi, Laszlo Hegedüs, Steen Joop Bonnema, Andrea Frasoldati, Laszlo Jambor, Gabor Laszlo Kovacs, Enrico Papini, Karoly Rucz, Gilles Russ, Zsolt Karanyi, Endre V. Nagy
Dátum:	2021
ISSN:	2235-0640 2235-0802
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Thyroid Journal. - 10 : 5 (2021), p. 416-424. -
További szerzők:	Hegedűs László Bonnema, Steen Joop Frasoldati, Andrea Jámbor László (1960-) (radiológus) Kovács Gábor László Papini, Enrico Rucz Károly Russ, Gilles Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM071707
Első szerző:	Szujó Szabina
Cím:	The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer : a bi-institutional study / Szujo Szabina, Sira Livia, Bajnok Laszlo, Bodis Beata, Gyory Ferenc, Nemes Orsolya, Rucz Karoly, Kenyeres Peter, Valkusz Zsuzsanna, Sepp Krisztian, Schmidt Erzsebet, Szabo Zsuszanna, Szekeres Sarolta, Zambo Katalin, Barna Sandor, Nagy Endre V., Mezosi, Emese
Dátum:	2017
ISSN:	1949-2553
Megjegyzések:	Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis.Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100?3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4?6 days after radioiodine therapy. Patients were re-evaluated 9?12 months later as well as at the end of follow up (median 37 months).Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). Noevidence of disease was found in 251 cases at 9?12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end offollow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%,62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately.Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban differentiated thyroid cancer radioiodine therapy SPECT/CT ATA risk classification ETA risk classification
Megjelenés:	Oncotarget. - 8 : 45 (2017), p. 79825-79834. -
További szerzők:	Sira Lívia (1973-) (endokrinológus) Bajnok László (1961-) (belgyógyász) Bódis Beáta Győry Ferenc (1969-) (kardiológus) Nemes Orsolya Rucz Károly Kenyeres Péter Valkusz Zsuzsanna Sepp Krisztián Schmidt Erzsébet Szabó Zsuszanna (Pécs) Szekeres Sarolta Zámbó Katalin Barna Sándor (1982-) (kutató orvos) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Mezősi Emese
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: